Press releases

BD MiniDraw™ Capillary Blood Collection System Enables Lab-Quality Blood Testing from Less Invasive Method than Venous Collection in More Convenient Locations FRANKLIN LAKES, N.J., Dec. 7, 2023...

FRANKLIN LAKES, N.J. (Dec. 5, 2023) – Today, in recognition of International Volunteer Day 2023, leading global medical technology company, BD (Becton, Dickinson and Company) (NYSE: BDX),...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series, which will...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety...

SiteRite™ 9 Ultrasound System Delivers Enhanced Image Quality and Vessel Assessment Tools to Aid in First Attempt IV Insertion Success FRANKLIN LAKES, N.J., Nov. 30, 2023 /PRNewswire/ -- BD...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Ronald (Ron) Silverman, MD, FACS, has been named executive vice president and...

WASHINGTON, D.C., USA, Nov. 20, 2023 – BD (Becton Dickinson and Company), a leading global medical technology company, and Bio Farma, a state-owned life science company in Indonesia, signed a...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday,...

Execution of BD 2025 Strategy Driving Durable, Broad-Based Growth Q4 revenue of $5.1 billion increased 6.8% as reported and 5.9% on a currency-neutral basis Q4 revenue from base business (which...

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.95 per common share, an increase of 4.4% from the previous quarter. The dividend...

New Peripheral Line Draw Solution Delivers First and Only Compatibility with Integrated Catheters, Bringing Elevated Standard of Care to More U.S. Hospitals FRANKLIN LAKES, N.J., Nov. 2, 2023...

Results of the SAFE-DCB Registry support long-term safety and effectiveness for the Lutonix™ DCB in a real-world patient population with femoropopliteal disease.

Company Ranks Top 2 in Healthcare Equipment and Services Industry FRANKLIN LAKES, N.J., Oct. 18, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of...

All Used Injection Devices Recycled; Next Stage of Pilot to Expand Regionally, Add Medical Devices FRANKLIN LAKES, N.J. and RUTLAND, Vt., Oct. 16, 2023 /PRNewswire/ -- BD (Becton, Dickinson and...

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will report its fiscal 2023 fourth quarter and full year financial results on...

FRANKLIN LAKES, N.J. (Oct. 1, 2023) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced Bridget Bagnato has been named president of BD...

Recognition underscores company's commitment to transparency and values FRANKLIN LAKES, N.J., Sept. 19, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences: 2023 Wells Fargo...

First patient enrollment in ARCH study begins investigation of the safety and effectiveness of the BD Liverty™ Transjugular Intrahepatic Portosystemic Shunt (TIPS) Stent Graft to reduce...

Increased manufacturing capacity combined with an expansion from 69 to 92 eligible countries, is expected to enable delivery of more than 320 million doses through 2030 Previously guaranteed...

Continues Strong Performance and Progress Toward Achieving BD 2025 Strategy; Advances Innovation Pipeline and Receives Clearance for Updated BD Alaris™ Infusion System Revenue of $4.9 billion...

Single Test on BD MAX™ System Identifies and Differentiates Multiple Respiratory Infectious Diseases from One Sample FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and...

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, payable on September 29, 2023 to holders of record on...

Reflects Commitment to Gender Equality and Progress in Advancing ESG Strategy FRANKLIN LAKES, N.J. (July 25, 2023) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...